180 related articles for article (PubMed ID: 35908276)
1. The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer.
Lo UG; Chen YA; Cen J; Deng S; Luo J; Zhau H; Ho L; Lai CH; Mu P; Chung LWK; Hsieh JT
Clin Transl Med; 2022 Aug; 12(8):e978. PubMed ID: 35908276
[TBL] [Abstract][Full Text] [Related]
2. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
3. Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
Qin C; Sheng Z; Huang X; Tang J; Liu Y; Xu T; Qiu X
Prostate; 2020 Sep; 80(13):1134-1144. PubMed ID: 32628304
[TBL] [Abstract][Full Text] [Related]
4. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
Zhang L; Xu LJ; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 May; 17(5):7045-7054. PubMed ID: 29568923
[TBL] [Abstract][Full Text] [Related]
5. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
6. CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation.
Lin Q; Cao J; Du X; Yang K; Yang X; Liang Z; Shi J; Zhang J
Cell Commun Signal; 2022 Mar; 20(1):31. PubMed ID: 35292057
[TBL] [Abstract][Full Text] [Related]
7. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.
Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N
Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728
[TBL] [Abstract][Full Text] [Related]
8. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
9. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
10. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
11. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract][Full Text] [Related]
12. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line.
Jackson DP; Watling D; Rogers NC; Banks RE; Kerr IM; Selby PJ; Patel PM
Melanoma Res; 2003 Jun; 13(3):219-29. PubMed ID: 12777975
[TBL] [Abstract][Full Text] [Related]
13. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH
Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315
[TBL] [Abstract][Full Text] [Related]
14. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
16. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
17.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
18. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling.
Collins AS; McCoy CE; Lloyd AT; O'Farrelly C; Stevenson NJ
PLoS One; 2013; 8(7):e69090. PubMed ID: 23894411
[TBL] [Abstract][Full Text] [Related]
19. Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.
Adisetiyo H; Liang M; Liao CP; Jeong JH; Cohen MB; Roy-Burman P; Frenkel B
J Cell Physiol; 2014 Sep; 229(9):1170-6. PubMed ID: 24752784
[TBL] [Abstract][Full Text] [Related]
20. Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies.
Morgan EL; Macdonald A
Viruses; 2020 Sep; 12(9):. PubMed ID: 32899142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]